The Cigna Group is one of the largest U.S. employee benefits organizations, operating through two primary segments: Evernorth Health Services (79% of 2025 adjusted revenues), which provides pharmacy benefit management, specialty pharmacy, and behavioral health services; and Cigna Healthcare (21%), which offers commercial medical insurance domestically and internationally. Following the divestiture of its Medicare businesses, CI is now a focused commercial health + PBM operator with reduced federal government exposure.

• Second-largest U.S. employee benefits organization by revenue, with significant scale in both commercial health insurance and PBM operations.
• Evernorth franchise benefits from a sticky pharmacy benefit platform processing 2.22B claims in 2025, with long-duration client relationships.
• Centene PBM services agreement (estimated 20M members won from CVS) demonstrates competitive win capability in PBM market share battles.
• Streamlined portfolio post-Medicare divestiture allows sharper focus on commercial health and pharmacy, improving margin profile.
• Low valuation (9.3x forward P/E) with strong buyback potential provides downside protection.

• Medicare divestiture closed (March 2025): Sold Medicare Advantage, Part D, and CareAllies to HCSC for $4.9B; CI now focused on Commercial + PBM with less federal exposure.
• FTC/Express Scripts settlement (February 2026): Resolved antitrust lawsuit over insulin pricing; agreed to concessions including moving Ascent GPO to U.S. and joining TrumpRx, reducing regulatory overhang.
• Q1 2026 beat: Adjusted EPS of $7.79 (+16% Y/Y) exceeded consensus by $0.18; full-year guidance raised $0.10. Evernorth revenues up 9% Y/Y.
• Planned ACA exit: CI will exit Individual ACA Exchange market by year-end 2026, citing limited scale relative to portfolio.

• Membership declines: Total medical customers fell ~5% in 2025 following divestitures; medical customer growth expected flat in 2026.
• Medical utilization pressure: Industrywide cost pressures from stop-loss plans and deferred care; MCR maintained at 83.7%-84.7% guidance reflects ongoing uncertainty.
• PBM regulatory risk: Intense political scrutiny on PBM rebate models; FTC action and Trump administration policies could pressure Evernorth economics.
• Leverage: Total debt/capital of ~39% following Express Scripts acquisition; though steadily deleveraging.